In Vitro Activity of Gepotidacin Against Recent Clinical Isolates of Yeasts (2021)

JMI Laboratories, North Liberty, Iowa, USA; Pfizer Inc., New York, NY, USA

Introduction

- Many invasive fungal infections are treated with azoles. The triazole class (fluconazole) is a component of Phase 3 clinical trials for the treatment of candidemia/invasive candidiasis (NCT05421858).
- Many have developed resistance to the *in vitro* activity against *Candida* spp., including *C. krusei* (reclassified *Pichia kudriavzevii*), *Aspergillus* spp., and other molds.
- This study determined the *in vitro* activity of gepotidacin and comparator agents against a collection of recent clinical isolates from the SENTRY Surveillance Program

Results

- Many demonstrated *in vitro* activity against isolates of yeasts and exhibited a modal MIC value of ≤0.06 mg/L:
  Candida fermentati ($MIC_{50/90}$, 0.008/0.06 mg/L),
  C. guilliermondii ($MIC_{50/90}$, 0.008/0.016 mg/L),
  C. quercitrusa (MIC, 0.016 mg/L), *Saprochaete clavate* (formerly *Geotrichum clavatum*; $MIC_{50/90}$, 0.03/0.06 mg/L),